BioSpace News Archive

Evelo Biosciences, a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that management will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12th 2:15 p.m. ET.

RenalytixAI plc (LSE: RENX) (NASDAQ: RNLX), announced today that KidneyIntelX™ more accurately predicted progressive kidney function decline and kidney failure in a multi-center, diverse cohort of 1,146 type 2 diabetes patients with early-stage (stages 1, 2, and 3) kidney disease versus the current standard of care.

Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced the appointment of Lauren Merendino as Chief Commercial Officer of Myovant Sciences, Inc., effective April 5, 2021.

Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present at two upcoming virtual conferences in April 2021:.

Journey Medical Corporation, a partner company of Fortress Biotech, Inc., announced that it has entered into an agreement with East West Bank in which EWB will provide a $7.5 million working capital line of credit.

Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced the successful completion of the safety run-in of the Stage 2 of the Phase 2 clinical study of prexigebersen, a liposomal Grb2 antisense, for the treatment of acute myeloid leukemia, in combination with frontline therapies, decitabine and venetoclax, in acute myeloid leukemia patients.

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system disorders, announced that the European Commission has granted Orphan designation for PBKR03, an adeno-associated virus -delivery gene therapy for the treatment of Krabbe disease.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its participation in the 20th Annual Needham Healthcare Conference to be held virtually from April 12 –15, 2021.

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointment of Jessie M. English, Ph.D. to its Board of Directors

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the 20th Annual Needham Virtual Healthcare Conference.